Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.140
+0.140 (4.67%)
At close: Nov 18, 2025, 4:00 PM EST
3.160
+0.020 (0.64%)
After-hours: Nov 18, 2025, 4:00 PM EST
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
48.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | 196.00K | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GRCE News
- 1 day ago - Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference - GlobeNewsWire
- 5 days ago - Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 7 days ago - Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting - GlobeNewsWire
- 26 days ago - Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review - GlobeNewsWire
- 2 months ago - Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting - GlobeNewsWire
- 2 months ago - Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 - GlobeNewsWire
- 2 months ago - Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 - GlobeNewsWire